31
Barsoum James, Du Zhenjian, Dahl Thomas A, Mcleod Matthew: Methods of determining cancer prognosis via natural killer cell activity. Synta Pharmaceuticals, Barsoum James, Du Zhenjian, Dahl Thomas A, Mcleod Matthew, DAVIS Steven G, October 26, 2006: WO/2006/113493 (21 worldwide citation)

A method of determining a prognosis for a subject undergoing cancer therapy with an agent that activates heat shock protein 70 (Hsp70) includes the step of comparing natural killer (NK) cell activity in a test sample with NK cell activity in a control sample. The control sample can be taken from the ...


32
Chen Shoujun, Koya Keizo, Demko Zachary, Sun Lijun: Compounds for treating proliferative disorders. Synta Pharmaceuticals, Chen Shoujun, Koya Keizo, Demko Zachary, Sun Lijun, DAVIS Steven G, February 28, 2008: WO/2008/024303 (21 worldwide citation)

Disclosed are compounds of formulae (I), (III), (IV), (VII), (X), (XI), (XII), (XIII) and (XIV), wherein the variabables are as defined in the claims, and methods of using compounds of the invention for treating a subject with a proliferative disorder, such as cancer, and methods for treating disord ...


33
LI Wei, MILLER Michael, FISHKIN Nathan, CHARI Ravi V J: DÉRIVÉS CYTOTOXIQUES DE BENZODIAZÉPINE, CYTOTOXIC BENZODIAZEPINE DERIVATIVES. IMMUNOGEN, LI Wei, MILLER Michael, FISHKIN Nathan, CHARI Ravi V J, DAVIS Steven G, September 27, 2012: WO/2012/128868 (21 worldwide citation)

The invention relates to novel benzodiazepine derivatives with antiproliferative activity and more specifically to novel benzodiazepine compounds of formula (I)-(VII). The invention also provides conjugates of the benzodiazepine compounds linked to a cell-binding agent. The invention further provide ...


34
Barsoum James: Bis(thio-hydrazide amides) for increasing hsp70 expression. Synta Pharmaceuticals, Barsoum James, DAVIS Steven G, May 26, 2006: WO/2006/055747 (20 worldwide citation)

A method of treating a Hsp70-responsive disorder in a subject includes administering to the subject an effective amount of a compound represented by Structural Formula (I), or a pharmaceutically acceptable salt or solvate thereof. Formula (I) Y is a covalent bond or an optionally substituted straigh ...


35

36

37
PEREIRA OSWY: Analogues for the treatment or prevention of flavivirus infections. VERTEX PHARMACEUTICALS INCORPORATED, Davis Steven G, September 29, 2011: WO/2011/119858 (19 worldwide citation)

Compounds represented by Formula (I) or pharmaceutically acceptable salts thereof, wherein A, B, B', X, Y, R1; R2, R2', R3, R3', R4, R5, R5'm, n, or p are as defined herein, are useful for treating flaviviridae viral infections.


38
Kostik Elena, Vaghefi Farid, Liang Guiqing, Koya Keizo, Sun Lijun, Tatsuta Noriaki, Chen Shoujun, Inoue Takayo, Xia Zhi Qiang: Bis(thio-hydrazide amide) salts for treatment of cancers. Synta Pharmaceuticals, Kostik Elena, Vaghefi Farid, Liang Guiqing, Koya Keizo, Sun Lijun, Tatsuta Noriaki, Chen Shoujun, Inoue Takayo, Xia Zhi Qiang, DAVIS Steven G, January 26, 2006: WO/2006/009940 (18 worldwide citation)

Disclosed are bis(thio-hydrazide amide) disalts, which are represented by Structural Formula (I) Y is a covalent bond or a substituted or unsubstituted straight chained hydrocarbyl group. R1-R4 are independently -H, an aliphatic group, a substituted aliphatic group, an aryl group or a substituted ar ...


39
Barsoum James, Du Zhenjian: Methods of increasing natural killer cell activity for therapy. Synta Pharmaceuticals, Barsoum James, Du Zhenjian, DAVIS Steven G, October 26, 2006: WO/2006/113572 (18 worldwide citation)

Methods of employing bis(thio-hydrazide amides) to increase NK cell activity in a subject in need thereof, e.g., a subject with an infection or an immunodeficiency, are provided such that the disorder is not cancer, a proliferative cell disorder, a non-infective heat shock protein 70 (Hsp70) respons ...


40
Bergeron Raymond J: Desferrithiocin polyether analogues. University Of Florida Research Foundation, Bergeron Raymond J, DAVIS Steven G, October 12, 2006: WO/2006/107626 (18 worldwide citation)

Compounds represented by structural formulas described herein, such as Structural Formula (I): are useful in treating conditions such as metal overload, oxidative stress, and neoplastic and preneoplastic conditions.